Ajanta Pharma has established itself as a meaningful niche player in the US generics market.
Our strategy is to have a selective play in this market with launching limited competition products. Currently we have 43 final ANDA approvals, out of which 39 are commercialized. Ajanta is awaiting US FDA approval for 22 ANDAs. We plan to file 10-12 ANDAs every year. All the products are marketed through our subsidiary Ajanta Pharma USA Inc. For more details on this subsidiary, please click here.
We continue to work with all major distributors in the market with an impeccable service record which has strengthened our position as a partner of first-choice. We have twice received DIANA award for ‘Best Overall Generic Manufacturer’ in less than $100 million category.